About Technology Issues FAQ

Links

Second-line bevacizumab-containing therapy in patients with triple-negative breast cancer: subgroup analysis of the RIBBON-2 trial

Second-line bevacizumab-containing therapy in patients with triple-negative breast cancer: subgroup analysis of the RIBBON-2 trial — Distribution of the number of citations over years.

site/software © exaly; All materials licenced under CC by-SA.